[Simultaneous Quadruple Therapy In The Treatment Of Helicobacter Pylori During Peptic Ulcer Disease].

Abstract

Helicobacter pylori (Hp) infection plays an important role in the genesis of peptic ulcer disease. In the absence of susceptibility testing, concomitant quadruple therapy is one of the most widely used eradication methods. In the absence of a study on four-drug therapy and the difficulty of studying antibiotic susceptibility in our context, we initiated this work in order to evaluate the efficacy of an empirical treatment with concomitant four-drug therapy currently available.

Method: This was a prospective study from May 2020 to April 2021 in the Hepato Gastroenterology Department of the Gabriel Touré University Hospital, the "Les ETOILES" Clinics, "Promenade des Angevins", FARAKO". The study included peptic ulcer patients who underwent gastric biopsies for Hp, concomitant quadruple therapy, and patients were screened for endoscopic ulcer control with biopsies for Hp eradication at least four weeks after treatment.

Result: We obtained an overall frequency of Hp infection at 79% of the general population in peptic ulcer disease. This frequency was 80% in duodenal ulcer and 77.4% in gastric ulcer. The mean age was 49.05 ±17.25 years with extremes of 22 and 105 years and a sex ratio of 2.4 M/F. Epigastric pain dominated the symptomatology and with 81.6% of cases. The eradication rate was 94.7% (36/38) of cases with a healing rate of 89.5% (34/38) of cases. Histological lesions remained almost constant after treatment.

Conclusion: Concomitant quadruple therapy is effective on Hp eradication.